We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
- Authors
Hennessy, Bryan T J; Timms, Kirsten M; Carey, Mark S; Gutin, Alexander; Meyer, Larissa A; Flake, Darl D, 2nd; Abkevich, Victor; Potter, Jennifer; Pruss, Dmitry; Glenn, Pat; Li, Yang; Li, Jie; Gonzalez-Angulo, Ana Maria; McCune, Karen Smith; Markman, Maurie; Broaddus, Russell R; Lanchbury, Jerry S; Lu, Karen H; Mills, Gordon B
- Abstract
The prevalence of BRCA(1/2) mutations in germline DNA from unselected ovarian cancer patients is 11% to 15.3%. It is important to determine the frequency of somatic BRCA(1/2) changes, given the sensitivity of BRCA-mutated cancers to poly (ADP ribose) polymerase-1 (PARP1) inhibitors and platinum analogs.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 22, p3570
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.27.2997